IPD Analytics speaks about key takeaways from the AJMC 2024 Annual Conference

This article explains the ins and outs of digital therapeutics.

IPD presents at the AMCP 2024 annual meeting discussing the current promise and future potential of gene and cell therapies.

IPD Analytics LLC. discusses the up to 50 generics that could be approved this year, including Victoza to treat patients with diabetes.

Jeffrey Casberg of IPD Analytics LLC, talks about how payers are thinking about weight-loss drugs.

A CPO in the C-suite determines how a health system can move from a cost center to a revenue center with healthy operating margins

Casberg is Vice President of Clinical Pharmacy at IPD Analytics LLC and a member of the Managed Healthcare Executive editorial advisory...

Explore the evolving landscape of biosimilars in the US market, from legislative influences to industry challenges, with expert insights.

Amgen has thrown its hat in the ring to launch a US biosimilar to Regeneron’s Eylea eye-disease blockbuster.

The U.S. market for specialty generic drugs hit $23 billion in 2021, and is expected to reach nearly $43 billion by 2027, driven by the...

A wave of blockbuster generic drugs launches, new brand drugs that address unmet needs, and legislation that would bring transparency to...

The Centers for Medicare and Medicaid Services (CMS) has released the list of the first 10 drugs to be negotiated under the Inflation...

We need a streamlined approach where stakeholders can perform all critical tasks — from enrollment and patient consent to prior...

We need a streamlined approach where stakeholders can perform critical tasks — from enrollment and patient consent to prior authorization

Briana Contreras, an editor with Managed Healthcare Executive, and Peter Wehrwein, managing editor of MHE, got to chatting with the...

The Academy of Managed Care Pharmacy is throwing its support behind federal legislation that would create a Medicare benefit category for...

Jeffrey Casberg, Senior Director of Pharmacy at IPD Analytics discusses some of the high-impact specialty drugs in various therapeutic...

Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne...

Dr. Billings, PharmD, BCGP, and Dr. Mahler, PhD, of IPD Analytics discuss specialized treatment with Beta Thalassemia at AMCP 2023. By...

A deep dive into the relationships between manufacturers of specialty drugs and the pharmacies they choose for their limited and...

PARPi monotherapy has been a milestone in the management of many BRCA1/2-mutated cancers, offering patients and prescribers the hope of...

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic,...

Julie Kendle, Director, Clinical Pharmacy Director, Clinical Pharmacy at IPD Analytics addresses tips on improving accumulators and ways...

The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already...